UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
19.91
-0.55 (-2.69%)
Mar 9, 2026, 4:00 PM EDT - Market closed
UroGen Pharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -153.49 | -126.87 | -102.24 | -109.78 | -110.82 | Upgrade
|
| Depreciation & Amortization | 2.41 | 1.19 | 1.71 | 1.82 | 1.77 | Upgrade
|
| Other Amortization | - | - | - | 1.75 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 3.13 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.88 | -2.89 | -1.03 | -0.5 | 0.48 | Upgrade
|
| Stock-Based Compensation | 11.96 | 13.11 | 9.34 | 10.58 | 23.11 | Upgrade
|
| Other Operating Activities | 3.34 | 13.77 | 12.52 | 13.75 | 13.67 | Upgrade
|
| Change in Accounts Receivable | -12.78 | -4.86 | -2.74 | -0.99 | -4.67 | Upgrade
|
| Change in Inventory | -7.24 | -3.55 | -1.35 | -0.36 | -2.87 | Upgrade
|
| Change in Accounts Payable | 0.29 | 10.89 | 4.16 | 0.28 | 2 | Upgrade
|
| Change in Income Taxes | 0.11 | 0.6 | 0.18 | 0.18 | 0.13 | Upgrade
|
| Change in Other Net Operating Assets | -8.3 | 1.86 | 3.09 | -4.29 | -7.69 | Upgrade
|
| Operating Cash Flow | -162.44 | -96.77 | -76.38 | -87.56 | -84.89 | Upgrade
|
| Capital Expenditures | -0.29 | -0.3 | -0.19 | -0.25 | -0.75 | Upgrade
|
| Investment in Securities | 61.85 | -20.32 | -0.76 | 1.31 | 4.82 | Upgrade
|
| Investing Cash Flow | 61.56 | -20.61 | -0.95 | 1.06 | 4.07 | Upgrade
|
| Long-Term Debt Issued | - | 24.49 | - | 95.78 | - | Upgrade
|
| Long-Term Debt Repaid | -1.86 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -1.86 | 24.49 | - | 95.78 | - | Upgrade
|
| Issuance of Common Stock | 41.77 | 151.49 | 68.23 | 1.51 | 72.46 | Upgrade
|
| Other Financing Activities | - | 18.64 | 48.7 | -0.16 | -0.14 | Upgrade
|
| Financing Cash Flow | 39.92 | 194.62 | 116.93 | 97.13 | 72.32 | Upgrade
|
| Net Cash Flow | -60.97 | 77.24 | 39.6 | 10.64 | -8.5 | Upgrade
|
| Free Cash Flow | -162.73 | -97.06 | -76.57 | -87.81 | -85.64 | Upgrade
|
| Free Cash Flow Margin | -148.22% | -107.37% | -92.57% | -136.45% | -178.27% | Upgrade
|
| Free Cash Flow Per Share | -3.38 | -2.26 | -2.66 | -3.85 | -3.83 | Upgrade
|
| Levered Free Cash Flow | -99.42 | -48.21 | -35.16 | -42.79 | -44.14 | Upgrade
|
| Unlevered Free Cash Flow | -89.83 | -40.38 | -25.96 | -39.27 | -44.14 | Upgrade
|
| Change in Working Capital | -27.91 | 4.93 | 3.34 | -5.18 | -13.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.